Context Therapeutics Inc., a clinical-stage biopharmaceutical company, has appointed Dr. Karen Chagin as Chief Medical Officer, effective June 9, 2025. Dr. Chagin, who has extensive experience in T cell therapies for solid tumors, previously held a senior position at Adaptimmune Therapeutics. She succeeds Dr. Karen Smith, who will remain on the company's Board of Directors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.